The European Medicines Agency (EMA) has started a rolling review of Revolution Medicines’ experimental treatment for metastatic pancreatic cancer. While no efficacy/safety results were cited, the regulatory milestone is a positive step that can improve the perceived probability of eventual approval.
The European Medicines Agency (EMA) has started a rolling review of Revolution Medicines’ experimental treatment for metastatic pancreatic cancer. While no efficacy/safety results were cited, the regulatory milestone is a positive step that can improve the perceived probability of eventual approval.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
